Most Viewed Articles - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Most Viewed Articles

Boehringer Ingelheim Settles False Claims Act Allegations for $95 Million

November 5, 2012

ePT--the Electronic Newsletter of Pharmaceutical Technology

Boehringer Ingelheim has agreed to pay $95 million to settle allegations that it improperly promoted four of its drugs.

Mean Kinetic Relative Humidity: A New Concept for Assessing the Impact of Variable Relative Humidity on Pharmaceuticals

November 2, 2012

Pharmaceutical Technology

This article introduces"mean kinetic relative humidity" for evaluating the impact of humidity variability.

An Industry Perspective on Harmonization and Implementation of ICH and USP Requirements

November 2, 2012

Pharmaceutical Technology

The US Pharmacopeia's revised General Chapters on elemental impurity limits and testing procedures are set to take effect in December 2012.

A Troubleshooting Guide for Topical Drug Manufacturing

November 2, 2012

Pharmaceutical Technology

Consider critical process parameters and strategies to optimize the manufacturing process.

Examining the Growing Challenge of Extractables and Leachables

November 2, 2012

Pharmaceutical Technology

Experts share insight into extractables and leachables testing, including high-risk products, analytical testing, and regulatory requirements from FDA and EMA.

Optimizing Early-Stage Drug Development

November 2, 2012

Pharmaceutical Technology

Pharmaceutical companies and contract service providers adapt strategies and capabilities to reduce costs and accelerate drug-development timelines.

Novartis Invests US$500 Million in New Biologics Facility in Singapore

October 31, 2012

Novartis is investing more than half a billion US dollars in the construction of a new state-of-the-art biotechnology production site in Singapore for the manufacturing of drugs based on cell culture technology.

Third-Quarter 2012 Financial Reports Show Novartis and Merck Down

October 30, 2012

ePT--the Electronic Newsletter of Pharmaceutical Technology

Pharmaceutical industry leaders Novartis and Merck—among others—released second-quarter 2012 results showing global sales down in third-quarter 2012, with growth in key pharmaceutical products helping to offset losses due to patent expirations.

FDA Issues 483 to New England Compounding Center

October 29, 2012

ePT--the Electronic Newsletter of Pharmaceutical Technology

New England Compounding Center gets 483 after linked fungal meningitis outbreak.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Click here